This Event is licensed under the Creative Commons BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Event: 239
Key Event Title
Activation, Pregnane-X receptor, NR1l2
Short name
Biological Context
Level of Biological Organization |
---|
Molecular |
Cell term
Cell term |
---|
eukaryotic cell |
Organ term
Key Event Components
Process | Object | Action |
---|---|---|
signaling | nuclear receptor subfamily 1 group I member 2 | increased |
Key Event Overview
AOPs Including This Key Event
AOP Name | Role of event in AOP | Point of Contact | Author Status | OECD Status |
---|---|---|---|---|
Nuclear receptor induced TH Catabolism and Developmental Hearing Loss | MolecularInitiatingEvent | Katie Paul Friedman (send email) | Open for adoption | Under Development |
PXR activation leads to liver steatosis | MolecularInitiatingEvent | John Frisch (send email) | Under development: Not open for comment. Do not cite |
Taxonomic Applicability
Life Stages
Life stage | Evidence |
---|---|
Adult | High |
Juvenile | Moderate |
Sex Applicability
Term | Evidence |
---|---|
Unspecific | High |
Key Event Description
Pregnane X receptor (PXR), also known as steroid NR subfamily 1, group I, member 2 (NR1I2), is a nuclear receptor that can be activated by pregnenolone and progesterone and many chemicals due to low specificity; once activated it binds to Retinoid X receptor (RXR) and increases upregulation of target genes (Mellor et al. 2016). PXR has an important role in lipid homeostasis by regulating the rate of lipid intake particularly through activation of cluster of differentiation 36, also known as platelet glycoprotein 4 [(CD36) (Zhou et al. 2006; Gwag et al. 2019)].
How It Is Measured or Detected
Pregnane X receptor (PXR) is measured by changes in gene expression and protein levels. Effects of PXR on expression of downstream genes can be investigating using metabolomics and RT-qPCR approaches.
Domain of Applicability
Life Stage: Applies to all life stages with a liver. Older individuals are more likely to manifest this adverse outcome pathway (adults > juveniles) due to accumulation of triglycerides.
Sex: Applies to both males and females.
Taxonomic: Appears to be present broadly in vertebrates, with most representative studies in mammals (humans, lab mice, lab rats).
References
Gwag, T., Meng, Z., Sui, Y., Helsley, R.N., Park, S.-H., Wang, S., Greenberg, R.N., and Zhou, C. 2019. Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis. Journal of Hepatology 70: 930–940.
Mellor, C.L., Steinmetz, F.P., and Cronin, T.D. 2016. The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways. Critical Reviews in Toxicology 46(2): 138-152. DOI:10.3109/10408444.2015.1089471
Zhou, J., Zhai, Y., Mu, Y., Gong, H., Uppal, H., Toma, D., Ren, S., Evans, R.M., and Xie, W. 2006. A Novel Pregnane X Receptor-mediated and Sterol Regulatory Element-binding Protein-independent lipogenic pathway. The Journal of Biological Chemistry 281(21): 15013–15020.